Delaware court invalidates Heron Cinvanti patent claims in Azurity litigation

Heron Therapeutics Inc

Heron Therapeutics Inc

HRTX

0.00
  • Heron Therapeutics lost a Delaware federal court ruling in its CINVANTI patent dispute with Azurity Pharmaceuticals.
  • The court held asserted claims in U.S. Patent Nos. 12,115,255 and 12,290,520 invalid.
  • Heron plans to appeal to the U.S. Court of Appeals for the Federal Circuit.
  • The ruling does not affect prior settlement agreements tied to CINVANTI or APONVIE.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020812PRIMZONEFULLFEED9730453) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.